Interesting RDNT Put And Call Options For September 18th

RadNet (RDNT) at $72.04: selling the $70 put (bid $6.80) would obligate purchase at $70 giving a net cost basis of $63.20 and is modeled as having a 62% chance to expire worthless, producing a 9.71% return (14.42% annualized) on the cash commitment. Alternatively, selling the $75 covered call (bid $7.80) against shares bought at $72.04 would cap upside at $75 but yield a 14.94% total return if called by the September 18 expiration, with a 45% probability of expiring worthless and a 10.83% YieldBoost (16.07% annualized). Implied volatility is ~45% on the put and 44% on the call versus a trailing 12-month volatility of 43%.

Analysis

Market structure: The options flow described directly benefits income/option-writer investors and RadNet (RDNT) shareholders who can monetize sideways price action; market makers and brokers also collect spreads/commissions. The put ($70 bid $6.80) implies a net cost basis of $63.20 if assigned and a 62% chance to expire worthless; the covered call ($75 bid $7.80) offers ~14.9% capped return to current holders with a 45% chance to expire worthless. Given implied vol (44–45%) is only ~2pp above realized (43%), options are modestly rich but not extreme — favoring systematic yield strategies over directional gamma plays.

Risk assessment: Tail risks include a Medicare/insurer reimbursement cut, large malpractice or regulatory action, or a material outpatient volume shock; each could compress EBITDA >20% and push shares >30% lower within 3–6 months. Immediate risk (days) is assignment and liquidity; short-term (weeks–months) risk is earnings and policy headlines (Medicare rule windows typically 30–90 days); long-term risks are secular pricing pressure from larger consolidated providers or AI-driven margin shifts over 12–36 months. Hidden dependencies: low open interest or wide bid/ask in RDNT options can make rolling/closing costly; assignment creates concentrated healthcare exposure.

Trade implications: Direct play — sell-to-open RDNT Sep $70 put size = 1–2% portfolio notional (target premium capture 9.7%, annualized 14.4%); set buy-write stop if RDNT < $60 or IV > 60%. Covered-call: existing shareholders sell Sep $75 for a net total return target 14.9%; if expecting upside, avoid and instead buy a 0.5–1% long position in RDNT + buy $65 protective puts (protects below ~$65). For higher conviction, use a collar: long RDNT, sell $75 call, buy $65 put to cap downside to ~9–12% over the same horizon.

Contrarian angles: Consensus treats these as conservative yield plays but underestimates assignment/operational risk — cheap-looking premiums (10–16% YB) can hide 30% downside in tail events; conversely, the market may be underpricing a consolidation play if RadNet executes M&A or improves referral share — a binary event that could rerate shares +25–40% suddenly. Historical parallel: similar income trades in regional healthcare post-2018 reimbursement uncertainty produced steady premium income but required active roll/assignment management. Actionable edge: size as yield trades (small, defined allocation), not as pure directional longs unless you have conviction on reimbursement and volume trends within 90–180 days.

Key Decisions for Investors

• Sell-to-open RDNT Sep $70 put (collect $6.80) sized to 1–2% of portfolio notional; target cash allocation = strike*$contracts if assigned; plan: keep premium if expires (62% odds) or accept assignment at $63.20; close/roll if RDNT falls below $60 or IV rises above 60%.
• If long RDNT shares, implement covered call: sell Sep $75 for $7.80 to lock an incremental 10.8% yield (14.9% total to $75); exit/roll if RDNT > $80 or positive catalyst (earnings/M&A) within 30 days to avoid giving up >10% upside.
• Use a collar for directional exposure: buy RDNT up to 1–2% portfolio, sell Sep $75 call and buy Sep $65 put (approx cost-neutral target) to cap downside to ~9–12% over the next 3–6 months while retaining moderate upside.
• Avoid larger directional longs >3% of portfolio until confirmation of patient volumes and reimbursement stability over next 60–90 days; monitor CMS/insurer headlines and RDNT quarterly guidance as primary catalysts.